Search Results - "Baer, M. R."

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis by Mascarenhas, J., Kosiorek, H., Prchal, J., Yacoub, A., Berenzon, D., Baer, M. R., Ritchie, E., Silver, R. T., Kessler, C., Winton, E., Finazzi, M. C., Rambaldi, A., Vannucchi, A. M., Leibowitz, D., Rondelli, D., Arcasoy, M. O., Catchatourian, R., Vadakara, J., Rosti, V., Hexner, E., Kremyanskaya, M., Sandy, L., Tripodi, J., Najfeld, V., Farnoud, N., Salama, M. E., Weinberg, R. S., Rampal, R., Goldberg, J. D., Mesa, R., Dueck, A. C., Hoffman, R.

Get full text

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia by Lancet, J E, Gojo, I, Burton, M, Quinn, M, Tighe, S M, Kersey, K, Zhong, Z, Albitar, M X, Bhalla, K, Hannah, A L, Baer, M R

“…Heat shock protein 90 (Hsp90) is a molecular chaperone with many oncogenic client proteins. The small-molecule Hsp90 inhibitor alvespimycin, a geldanamycin…”
Get full text

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide by Kayser, S, Krzykalla, J, Elliott, M A, Norsworthy, K, Gonzales, P, Hills, R K, Baer, M R, Ráčil, Z, Mayer, J, Novak, J, Žák, P, Szotkowski, T, Grimwade, D, Russell, N H, Walter, R B, Estey, E H, Westermann, J, Görner, M, Benner, A, Krämer, A, Smith, B D, Burnett, A K, Thiede, C, Röllig, C, Ho, A D, Ehninger, G, Schlenk, R F, Tallman, M S, Levis, M J, Platzbecker, U

“…Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to…”
Get full text

A reaction progress variable modeling approach for non-ideal multiphase explosives by Ruggirello, K.P., DesJardin, P.E., Baer, M.R., Kaneshige, M.J., Hertel, E.S.

“…► A reaction progress variable description for non-ideal multiphase explosives is developed. ► The formulation is unique – a reaction progress variable for…”
Get full text

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia by Metzeler, K H, Maharry, K, Kohlschmidt, J, Volinia, S, Mrózek, K, Becker, H, Nicolet, D, Whitman, S P, Mendler, J H, Schwind, S, Eisfeld, A-K, Wu, Y-Z, Powell, B L, Carter, T H, Wetzler, M, Kolitz, J E, Baer, M R, Carroll, A J, Stone, R M, Caligiuri, M A, Marcucci, G, Bloomfield, C D

“…Acute myeloid leukemia (AML) is hypothesized to be sustained by self-renewing leukemia stem cells (LSCs). Recently, gene expression signatures (GES) from…”
Get full text

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia by Whitman, S P, Caligiuri, M A, Maharry, K, Radmacher, M D, Kohlschmidt, J, Becker, H, Mrózek, K, Wu, Y-Z, Schwind, S, Metzeler, K H, Mendler, J H, Wen, J, Baer, M R, Powell, B L, Carter, T H, Kolitz, J E, Wetzler, M, Carroll, A J, Larson, R A, Marcucci, G, Bloomfield, C D

Get full text

Activation of a novel palmitoyltransferase ZDHHC14 in acute biphenotypic leukemia and subsets of acute myeloid leukemia by Yu, L, Reader, J C, Chen, C, Zhao, X F, Ha, J S, Lee, C, York, T, Gojo, I, Baer, M R, Ning, Y

Get full text

Breast cancer resistance protein (BCRP MXR ABCG2) in acute myeloid leukemia: discordance between expression and function by SUVANNASANKHA, A, MINDERMAN, H, O'LOUGHLIN, K. L, NAKANISHI, T, GRECO, W. R, ROSS, D. D, BAER, M. R

“…Data on breast cancer resistance protein (BCRP, MXR, ABCG2) expression in acute myeloid leukemia (AML) have been inconsistent, possibly due to use of different…”
Get full text

Serotonin syndrome caused by interaction between citalopram and fentanyl by Ailawadhi, S., Sung, K.‐W., Carlson, L. A., Baer, M. R.

“…Summary Objective:  To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history,…”
Get full text

Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461 by Byrd, J C, Weiss, R B, Arthur, D C, Lawrence, D, Baer, M R, Davey, F, Trikha, E S, Carroll, A J, Tantravahi, R, Qumsiyeh, M, Patil, S R, Moore, J O, Mayer, R J, Schiffer, C A, Bloomfield, C D

“…To examine the prognostic significance of extramedullary leukemia (EML) at presentation in patients with t(8;21)(q22;q22) karyotype. Consecutive patients with…”
Get more information

Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients by HAHN, T, RONDEAU, C, CZUCZMAN, M. S, SLACK, J, WETZLER, M, MOOKERJEE, B. K, SILVA, J, MCCARTHY, P. L, SHAUKAT, A, JUPUDY, V, MILLER, A, ALAM, A. R, BAER, M. R, BAMBACH, B, BERNSTEIN, Z, CHANAN-KHAN, A. A

“…We examined the incidence, risk factors and associated mortality of acute renal failure requiring dialysis (Renal Bearman Grade [BG] 3) in a 3-year cohort of…”
Get full text

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 by Baer, M R, George, S L, Sanford, B L, Mrózek, K, Kolitz, J E, Moore, J O, Stone, R M, Powell, B L, Caligiuri, M A, Bloomfield, C D, Larson, R A

“…Untreated de novo ( n =421) and secondary ( n =189) acute myeloid leukemia (AML) patients ⩾60 years received intensified chemotherapy, including daunorubicin…”
Get full text

Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered by BYRD, J. C, DODGE, R. K, SCHIFFER, C. A, BLOOMFIELD, C. D, CARROLL, A, BAER, M. R, EDWARDS, C, STAMBERG, J, QUMSIYEH, M, MOORE, J. O, MAYER, R. J, DAVEY, F

“…To examine the effect of single compared with repetitive (at least three) cycles of high-dose cytarabine after induction therapy for patients with acute…”
Get full text

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms by Berdeja, J., Palandri, F., Baer, M.R., Quick, D., Kiladjian, J.J., Martinelli, G., Verma, A., Hamid, O., Walgren, R., Pitou, C., Li, P.L., Gerds, A.T.

“…•Effective in myeloproliferative neoplasms previously treated with ruxolitinib.•Higher responses in polycythemia vera and essential thrombocythemia with…”
Get full text

HLA-DR antigen-negative acute myeloid leukemia by WETZLER, M, MCELWAIN, B. K, STEWART, C. C, BLUMENSON, L, MORTAZAVI, A, FORD, L. A, SLACK, J. L, BARCOS, M, FERRONE, S, BAER, M. R

“…Human leukocyte antigen (HLA) Class II antigens are variably expressed on acute myeloid leukemia (AML) blasts. The biological and clinical significance of HLA…”
Get full text

Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias by Tobin, L A, Robert, C, Rapoport, A P, Gojo, I, Baer, M R, Tomkinson, A E, Rassool, F V

“…Resistance to imatinib (IM) and other tyrosine kinase inhibitors (TKI)s is an increasing problem in leukemias caused by expression of BCR-ABL1. As chronic…”
Get full text

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503) by Blum, W, Sanford, B L, Klisovic, R, DeAngelo, D J, Uy, G, Powell, B L, Stock, W, Baer, M R, Kolitz, J E, Wang, E S, Hoke, E, Mrózek, K, Kohlschmidt, J, Bloomfield, C D, Geyer, S, Marcucci, G, Stone, R M, Larson, R A

“…In this prospective phase 2 clinical trial conducted by Cancer and Leukemia Group B (CALGB, now the Alliance), we studied decitabine as maintenance therapy for…”
Get full text

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia by Eisfeld, A-K, Kohlschmidt, J, Schwind, S, Nicolet, D, Blachly, J S, Orwick, S, Shah, C, Bainazar, M, Kroll, K W, Walker, C J, Carroll, A J, Powell, B L, Stone, R M, Kolitz, J E, Baer, M R, de la Chapelle, A, Mrózek, K, Byrd, J C, Bloomfield, C D

“…Core-binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22)/ RUNX1-RUNX1T1 or…”
Get full text

Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation : possible beneficial use of low molecular weight heparin by SIMON, M, HAHN, T, SLACK, J. L, WETZLER, M, HERZIG, G, SCHRIBER, J, MCCARTHY, P. L, FORD, L. A, ANDERSON, B, SWINNICH, D, BAER, M. R, BAMBACH, B, BERNSTEIN, S. H, BERNSTEIN, Z. P, CZUCZMAN, M. S

“…This retrospective cohort study of 462 consecutive adult allogeneic and autologous blood or marrow transplantation (BMT) patients compared the incidence of…”
Get full text

HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse by WETZLER, M, BAER, M. R, STEWART, S. J, DONOHUE, K, FORD, L, STEWART, C. C, REPASKY, E. A, FERRONE, S

“…Human leukocyte antigens (HLA) class I molecules restrict the interaction between cytotoxic T cells and target cells. Abnormalities in HLA class I antigen…”
Get full text